fincash logo SOLUTIONS
EXPLORE FUNDS
CALCULATORS
LOG IN
SIGN UP

Fincash » Search » Glaxosmithkline Pharmaceuticals Ltd

Glaxosmithkline Pharmaceuticals Ltd

Updated on April 14, 2019

Stock/Share Code - GLAXO

GlaxoSmithKline Pharmaceuticals is engaged interalia, in the Business of Manufacturing, Distributing and trading in Pharmaceuticals.

Below is the details of GLAXO Glaxosmithkline Pharmaceuticals Ltd

Market Cap₹22,611 Cr.
Current Price ₹1,299.9 as on 18 Apr 19
52 Week High / Low Price₹1,812 / ₹1,020
Face Value₹10
Stock P/E55.97
Book Value₹112.86
Dividend Yield1.31 %
ROCE25.61 %
ROE16.67 %
Sales Growth (3yrs)-4.41 %
SectorPharmaceuticals
IndustryPharmaceuticals - Multinational
Listed onBSE  AND  NSE
Company WebsiteCompany Website
Pros: Company has reduced debt. Company is virtually debt free. Company has been maintaining a healthy dividend payout of 90.92%
Cons: Stock is trading at 11.83 times its book value The company has delivered a poor growth of 1.80% over past five years.

Glaxosmithkline Pharmaceuticals Ltd Price Chart

Glaxosmithkline Pharmaceuticals Ltd Price Chart

Glaxosmithkline Pharmaceuticals Ltd Peer Comparison in Pharmaceuticals

S.No. Name CMP Rs. P/E Mar Cap Rs.Cr. Div Yld % NP Qtr Rs.Cr. Qtr Profit Var % Qtr Sales Var % Sales Qtr Rs.Cr. ROCE %
1. Merck ₹3,783.05 6.26 ₹5,227.17 Cr. 0.48 ₹715.34 Cr. 3106.36 14.47 204.39 19.38
2. Abbott India ₹7,825.1 36.15 ₹15,804.9 Cr. 0.74 ₹117.05 Cr. 1.44 7.51 947.65 40.63
3. Pfizer ₹3,221.55 34.92 ₹14,810.38 Cr. 0.62 ₹131.94 Cr. 51.24 12.54 513.79 21.48
4. Glaxosmi. Pharma ₹25 55.97 ₹22,610.62 Cr. 1.31 ₹112.97 Cr. 7.26 17.25 825.35 25.61
5. Sanofi India ₹5,766.95 36.12 ₹13,749.14 Cr. 1.19 ₹79.3 Cr. 4.34 8.35 726.40 26.45
6. Astrazeneca Phar ₹2,265.65 106.02 ₹5,071.01 Cr. 0.00 ₹29.09 Cr. 381.06 67.41 215.19 18.64
7. Novartis India ₹96.75 44.40 ₹1,711.69 Cr. 1.44 ₹12.87 Cr. 72.29 -13.12 135.62 17.32

Ready to Invest?
Talk to our investment specialist
Disclaimer:
By submitting this form I authorize Fincash.com to call/SMS/email me about its products and I accept the terms of Privacy Policy and Terms & Conditions.

Glaxosmithkline Pharmaceuticals Ltd Fundamentals

Quarterly Results

Quarterly reports are issued by companies every three months. Most companies have a financial year-end of Mar. 31 and quarters that end on June 30, Sept. 30, Dec. 31 and March 31.

Standalone Figures in Rs. Crores

Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018
Sales706705799706760583836704749736816825
YOY Sales Growth %14.28%8.23%11.37%-5.9%7.56%-17.36%4.65%-0.35%-1.45%26.21%-2.39%17.25%
Expenses577615658654623563644562594595651688
Material Cost %43.54%44.56%45.23%50.55%47.51%46.48%45.03%39.81%41.82%43.06%42.77%46.35%
Employee Cost %15.34%16.74%15.89%17.04%15.49%22.67%16.22%17.6%17.59%17.12%17.09%15.21%
Operating Profit129901415213720192142155140165137
OPM %18%13%18%7%18%3%23%20%21%19%20%17%
Other Income40261833412615121810345
Interest000000000000
Depreciation7577888139111212
Profit before tax1631111527817038199140164138156170
Tax %35%35%35%32%34%31%35%36%35%36%36%33%
Net Profit106729953113261309010689101113
NotesNotesNotesNotesNotesNotesNotesNotesNotesNotesNotesNotes

Profit & Loss

The profit and loss (P&L) statement is a financial statement that summarizes the revenues, costs and expenses incurred during a specified period, usually a fiscal quarter or year. The P&L statement is synonymous with the income statement. These records provide information about a company's ability or inability to generate profit" by increasing revenue, reducing costs or both. Some refer to the P&L statement as a statement of profit and loss, income statement, statement of operations, statement of financial results or income, earnings statement or expense statement.

Standalone Figures in Rs. Crores

Dec 2006Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Mar 2015Mar 2016Mar 2017Mar 2018TTM
Sales1,5251,5591,6651,8732,1122,3762,6262,5463,2882,8262,9032,8723,126
Sales Growth %4.77%2.22%6.8%12.45%12.76%12.51%10.55%-3.06%29.12%-14.03%2.72%-1.08%%
Expenses1,0641,0901,1571,2361,3741,5931,8112,0252,6612,3632,4852,3632,528
Material Cost %40.94%40.31%38.89%36.96%36.8%38.24%41.8%45.47%45.79%43.44%48.01%43.21%%
Manufacturing Cost %4.39%4.6%4.63%4.5%4.33%4.26%3.32%4.51%4.75%8.3%4.69%4.77%%
Employee Cost %9.93%9.5%10.11%10.89%11.11%12.1%14.98%14.22%15%15.69%16.64%18.23%%
Other Cost %14.48%15.48%15.84%13.62%12.85%12.47%8.87%15.32%15.41%16.19%16.26%16.09%%
Operating Profit462470508637737782815521627463418508598
OPM %30%30%31%34%35%33%31%20%19%16%14%18%19%
Other Income295339311153122-163492281481381207175
Interest1110100000001
Depreciation16161616182018202525273844
Profit before tax740791802773841599847729749576511542628
Tax %26%32%28%34%33%28%32%31%37%35%34%35%
Net Profit546538577512564431577502472375337352408
EPS in Rs30.0328.6830.6427.8730.1421.8630.3225.4317.1915.7519.8820.78
Dividend Payout %48%57%59%50%60%89%73%84%112%113%75%84%

Compounded Sales Growth

  • 10 Years:: 6.30%
  • 5 Years:: 1.80%
  • 3 Years:: -4.41%
  • TTM:: 8.44%

Compounded Profit Growth

  • 10 Years:: -1.43%
  • 5 Years:: -12.66%
  • 3 Years:: -12.09%
  • TTM:: 13.57%

Return on Equity

  • 10 Years:: 25.53%
  • 5 Years:: 19.80%
  • 3 Years:: 16.48%
  • TTM:: 16.67%

Balance Sheet

A balance sheet is a financial statement that reports a company's assets, liabilities and shareholders' equity at a specific point in time, and provides a basis for computing rates of return and evaluating its capital structure. It is a financial statement that provides a snapshot of what a company owns and owes, as well as the amount invested by shareholders. It is used alongside other important financial statements such as the income statement and statement of cash flows in conducting fundamental analysis or calculating financial ratios.

Standalone Figures in Rs. Crores

Dec 2006Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Mar 2015Mar 2016Mar 2017Mar 2018Sep 2018
Share Capital858585858585858585858585169
Equity Capital84.784.784.784.784.784.784.784.784.784.784.784.7
Reserves1,1101,2761,4561,6741,8461,8351,9251,9321,7672,1201,9441,9951,742
Borrowings6665555432210
Other Liabilities1,8366477357078561,0921,0781,1331,3928731,0061,9001,672
Trade Payables230.64226.3251.66291.37331.92198.34239.7281.9336.23395.58519.48642.92378.78
Total Liabilities3,0362,0142,2822,4722,7913,0173,0933,1553,2473,0803,0363,9813,584
Fixed Assets868790931099989100123204258325315
Gross Block253.63266.71282.15289.18318.4271.66272.04299.08319.19228.36305.22408.14
Accumulated Depreciation167.83179.24191.75196.37209.47172.53182.63199.01196.1324.3247.1983.57
CWIP95102191644621152686059231,008
Investments1,1391,333752191160160103584854484848
Other Assets1,8025881,4302,1672,5132,7422,8572,9352,9612,5552,1252,6862,213
Inventories240.95205.96228.38253.02281.54330.14282.04342.4368.86521.66425.48500.18470.43
Trade receivables60.4537.7757.9453.7347.0285.31115.996.39100.32126.57170.8146.96151.47
Cash Equivalents35.03154.99906.541672.61948.081984.092038.782027.141898.021377.68882.231279.69819.74
Loans n Advances1465.54188.88236.87187.35236.83180.16220.52222.7291.02232277.28355.4716.07
Total Assets3,0362,0142,2822,4722,7913,0173,0933,1553,2473,0803,0363,9813,584

Cash Flows

Cash flow is the net amount of cash and cash-equivalents being transferred into and out of a business. At the most fundamental level, a company’s ability to create value for shareholders is determined by its ability to generate positive cash flows, or more specifically, maximize long-term free cash flow.

Standalone Figures in Rs. Crores

Dec 2006Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Mar 2015Mar 2016Mar 2017Mar 2018
Cash from Operating Activity251307319503468322294267341138232475
Profit from operations518.67550.62597.95673.48762.23767.87815.97522.78628.11478.55419.93512.64
Working Capital Changes-41.9910.71-33.2522.2111.06-74.0538.791.66-30.17-125.04-29.47163.69
Taxes paid-224.09-246.81-240.23-177.43-304.67-309.3-313.8-242.05-250.13-215.24-158.19-201.56
Cash from Investing Activity6112787655102368-93198178499303-107
Fixed Assets Purchased-18.62-15.33-23.88-30.37-21.39-42.54-39.08-58.45-163.12-232.32-304.43-403.38
Fixed Assets Sold210.42240.420.279.50.772.460.3427.920.7324.1346.4318.07
Investments purchased-223.21-193.76-58.06000000000
Investments sold00785.35560.130.0105744.9110000
Cash from Financing Activity-269-299-355-392-294-392-437-490-497-638-511-307
Proceeds from Borrowings0.680.230000000000
Repayment of Borrowings00-0.12-0.23-0.26-0.26000000
Interest Paid-0.67-0.63-0.32-0.35-0.68-0.61-0.33-0.33-0.47-0.42-0.25-0.19
Dividends Paid-235.88-261.29-303.05-336.67-253.03-337.67-378.15-421.38-423.52-529.39-423.52-254.11
Net Cash Flow-13120751766275298-236-2522-12561

Ready to Invest?
Talk to our investment specialist
Disclaimer:
By submitting this form I authorize Fincash.com to call/SMS/email me about its products and I accept the terms of Privacy Policy and Terms & Conditions.

Ratios

Dec 2006Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Mar 2015Mar 2016Mar 2017Mar 2018
ROCE %51%51%47%46%47%48%50%35%41%28%22%26%
Debtor Days1491310813161411162119
Inventory Turnover6.656.987.677.787.907.778.588.159.246.356.136.20

Announcements & News

Recent Announcements

Annual Reports

How to Invest in Mutual Funds SIP Online?

  1. Open Free Investment Account for Lifetime at Fincash.com.
  2. Complete your Registration and KYC Process
  3. Upload Documents (PAN, Aadhaar, etc.). And, You are Ready to Invest! Get Started
  4. Invest in Mutual Funds which invests in Glaxosmithkline Pharmaceuticals Ltd & Get More Returns than Bank Deposit

Disclaimer:
All efforts have been made to ensure the information provided here is accurate as per time to time filling by company to exchanges. However, no guarantees are made regarding correctness of data. Investors are advised to validate/check information with exchanges or companies website before making any investment decisions.